Category Archives: HIV/TB Co-infection

Global Fund overhaul is well underway

By on .

Dr. Christoph Benn, director of Resource Mobilization and Donor Relations at the Global Fund to Fight AIDS, Tuberculosis and Malaria, updated global health community advocates Wednesday on the recent tumult at the multilateral organization. Since Columbian banker Gabriel Jaramillo was appointed to head up the Fund in January, the Secretariat has been consumed with “internal […]

Updated U.S. HIV treatment guidelines call for HIV treatment for all

By on .

The U.S. Department of Health and Human Services (HHS) released updated HIV treatment guidelines on March 27 which, among other things, maintain that all people living with HIV in the U.S. are now eligible to receive antiretroviral therapy (ART), regardless of CD4 cell count. Previous guidance recommended ART for those HIV-infected with a CD4 cell […]

Engaging the private sector to spur global development and save the foreign assistance budget

By on .

Foreign assistance experts gathered Wednesday to discuss the George W. Bush administration’s legacy on global development, focusing on lessons learned and applying them to the next decade and beyond, at an event hosted by the Consensus for Development Reform and the Modernizing Foreign Assistance Network in Washington. The panel discussion revolved around a central theme […]

Household-based HIV and TB intervention boosts HIV testing, lowers community TB prevalence

By on .

At the 19th Conference on Retroviruses and Opportunistic Infections in Seattle, Dr. Helen Ayles presented some key results on behalf of the ZAMSTAR team from the first randomized trial of a combined HIV and TB intervention strategy to demonstrate a reduction in population prevalence of tuberculosis. The study, conducted in 24 communities in Zambia and […]

High dose of new HIV drug might improve outcomes for HIV/TB co-infected

By on .

Treating patients co-infected with HIV and tuberculosis (TB) can be tricky – as rifampin, a key sterilizing drug in TB regimens – can reduce concentrations of antiretrovirals administered at the same time, as well as other drug-drug complications. Early efforts to combat this phenomenon have unearthed a potential treatment candidate – an increased dose of […]

Research to combat dual epidemics: A conversation with CDC’s Jordan Tappero

By on .

Science Speaks is delving into the global HIV and tuberculosis research and development efforts at the U.S. Centers for Disease Control and Prevention (CDC) with a series of interviews with staffers who are key to the success of their programs. For the fourth interview in the series, we spoke with Jordan W. Tappero, MD, MPH, who […]

Innovative programming to combat HIV, TB and cholera: A conversation with CDC’s John Vertefeuille

By on .

In this third post in a series of conversations with officials at the U.S. Centers for Disease Control and Prevention (CDC) discussing the CDC’s role in global HIV and tuberculosis research and development, Science Speaks sat down with John Vertefeuille, PhD – the country director for CDC in Haiti. There he leads a team of 55 and […]

HIV docs tell a powerful tale of combination prevention

By on .

“This is an extraordinary moment in the AIDS epidemic – we finally have the tools to turn the tide,” said Diane Havlir, MD, of the University of California San Francisco, speaking to the arsenal of HIV prevention interventions the AIDS community now has at its disposal to combat new infections worldwide. She spoke alongside a […]

NIAID announces funding ops for HIV Clinical Trial Networks, including TB and Hepatitis

By on .

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and the leading funder of AIDS research, issued long-awaited funding announcements to create leadership groups for clinical research networks in HIV that will also address tuberculosis (TB) and hepatitis—leading co-morbidities in persons with HIV infection. Requests for applications […]

CDC economic models show HIV treatment scale-up is cost-effective, can save money over time

By on .

New economic modeling shows that scaling up antiretroviral therapy (ART) for HIV/AIDS treatment and prevention in the developing world not only saves lives, but saves money too. Dr. John Blandford of  the Centers for Disease Control and Prevention’s Center for Global Health and his team of colleagues have found that cost savings from averted negative […]